Abstract
The introduction of recombinant DNA technology in 1978 enabled the gradual development of biosynthetic human (HM) insulin and at the same time started the era of monomeric insulin analogues. The risk of early postprandial hyperglycaemia and late postprandial hypoglycaemia is significantly reduced with monomeric insulin therapy.